Physician profile
Constantine N Kroustos
NPI 1750404984
$52,952.75
in general payments reported to CMS, 2019-2025
62 companies · $2,705 in 2025
The $2,705 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $16K · 2021: $1,515 · 2022: $1,732 · 2023: $1,744 · 2024: $1,582 · 2025: $2,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,030.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19,051.38 | 2019-2020 | |
| Lilly USA, LLC | $12,378.51 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,332.54 | 2019-2025 | Jardiance |
| Dexcom, INC. | $1,152.10 | 2019-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $1,122.55 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Novo Nordisk INC | $1,011.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $824.81 | 2019-2025 | Evenity, Prolia, Tepezza |
| Insulet Corporation | $632.38 | 2019-2023 | Omnipod |
| Abbott Laboratories | $606.83 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $448.34 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $405.09 | 2019-2025 | |
| Pfizer INC. | $313.97 | 2019-2025 | |
| Antares Pharma, INC. | $284.60 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Astrazeneca Pharmaceuticals LP | $274.06 | 2019-2023 | Farxiga |
| Abbvie INC. | $249.77 | 2019-2024 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $249.22 | 2019-2025 | Tymlos |
| Corcept Therapeutics | $247.39 | 2019-2025 | Korlym |
| Beta Bionics, INC. | $239.94 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amarin Pharma, INC. | $233.83 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $190.13 | 2019-2025 | Unithroid |
| Medtronic, INC. | $174.56 | 2021-2025 | Inceptiv, Minimed 780g |
| Novartis Pharmaceuticals Corporation | $167.42 | 2022-2025 | |
| Tandem Diabetes Care, INC. | $167.23 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $163.77 | 2019-2025 | Tirosint, Tirosint, Licart |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.81 | 2019-2024 | Cycloset |
| Mannkind Corporation | $142.50 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $119.89 | 2019-2023 | Steglujan, Steglatro, Segluromet |
| Alexion Pharmaceuticals, INC. | $117.90 | 2019-2025 | Strensiq |
| Cequr Corporation | $109.24 | 2022-2025 | Cequr Simplicity |
| Neurocrine Biosciences, INC. | $106.34 | 2024-2025 | |
| Almatica Pharma LLC | $103.77 | 2024-2025 | Teriparatide |
| Kowa Pharmaceuticals America, INC. | $102.47 | 2019-2024 | Livalo, Seglentis |
| Lifescan, INC. | $87.54 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $80.58 | 2021-2024 | Aveed |
| Madrigal Pharmaceuticals | $77.35 | 2025 | Rezdiffra |
| Kyowa Kirin, INC. | $75.97 | 2023-2025 | Crysvita |
| Ascendis Pharma Endocrinology INC | $65.01 | 2025 | Yorvipath |
| Regeneron Healthcare Solutions, INC. | $52.16 | 2019 | |
| Endo USA, INC. | $50.43 | 2024-2025 | Aveed |
| Ipsen Biopharmaceuticals, INC | $44.40 | 2019 | |
| Chiesi USA, INC. | $43.69 | 2024-2025 | Mycapssa |
| Sequel Med Tech, LLC | $40.11 | 2025 | Twiist |
| Halozyme INC | $35.66 | 2023 | |
| Medtronic Minimed, INC. | $33.16 | 2020 | |
| Amryt Pharma Holdings LTD | $32.38 | 2022 | |
| Horizon Therapeutics Plc | $32.30 | 2020-2021 | |
| Zealand Pharma US, INC. | $31.35 | 2021 | |
| Tolmar, INC. | $30.62 | 2023-2025 | Jatenzo |
| Shire North American Group INC | $27.70 | 2019 | |
| Becton, Dickinson and Company | $26.45 | 2022 | |
| Soleno Therapeutics, INC. | $23.73 | 2025 | Vykat Xr |
| Rhythm Pharmaceuticals, INC. | $23.62 | 2025 | Imcivree |
| Ultragenyx Pharmaceutical INC. | $21.89 | 2021 | |
| Valeritas, INC. | $18.79 | 2019 | |
| Recordati_rare_diseases_inc. | $17.49 | 2023 | Signifor Lar, Isturisa |
| Eisai INC. | $16.74 | 2025 | |
| Rgh Enterprises LLC | $16.23 | 2025 | |
| Averitas Pharma INC. | $15.95 | 2025 | Qutenza |
| Avvisto Therapeutics, LLC | $14.15 | 2025 | Cycloset |
| Ascensia Diabetes Care US INC. | $14.07 | 2024 | |
| Esperion Therapeutics, INC. | $14.00 | 2024 | Nexletol |
| Alfasigma USA, INC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constantine Kroustos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.